Skip to main content

Humanetics Corporation

  • | Biotech or pharma, therapeutic R&D

Humanetics, a private biopharmaceutical company based in Minnesota, is seeking up to US$20M in a Series B to develop BYOGRAYZ™ (aka BIO 300), a selective ERβ agonist which has produced excellent results as a medical countermeasure (MCM) to treat Acute Radiation Sickness (fully funded through EUA), in preventing tissue damage from RT in oncology (Phase 2b-ready in NSCLC), and in mitigating impaired pulmonary function in Long COVID (results recently announced).

Address

Excelsior
Minnesota
United States
Visit website

Contact Exhibitor


Loading
View all Exhibitors
Testimonials

Double Helix


 

Supporting Bank Sponsor


 

Premier Sponsors

Conference Sponsors